ENDV — Endonovo Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $0.37m
- $7.42m
- $0.14m
Annual cashflow statement for Endonovo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.44 | -17.3 | -0.396 | -3.1 | -18.5 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 2.03 | 12.5 | -2.89 | 0.247 | 15.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.879 | 1.62 | 1.89 | 1.22 | 2.01 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -2.88 | -2.54 | -0.742 | -0.987 | -0.679 |
| Capital Expenditures | -0.009 | -0.003 | — | 0 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -0.009 | -0.003 | — | 0 | — |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.18 | 2.18 | 0.736 | 1.06 | 0.593 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.289 | -0.36 | -0.005 | 0.073 | -0.086 |